PDCD1 and colorectal carcinoma: Regarding the safety of PD-1 inhibitors or apatinib monotherapies in advanced CRC patients, proceeding studies have suggested that pancreatitis, fatigue, and increased lipase levels are common adverse events with the use of a PD-1 inhibitor.